Staff Directory Contact Us

The Nathan S. Kline Institute for Psychiatric Research

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Balovaptan in Adults with Autism Spectrum Disorder with a 2-Year Open Label Extension

This study will evaluate the efficacy, safety, and pharmacokinetics of 10mg of oral administration balovaptan QD compared with matching placebo in adults (18 years and older) with ASD.

Study Length: 
Approximately 2.5 years
Disorder/Condition: 
Autism Spectrum Disorder
Inclusion Criteria: 

Males and Females, ages 18+ with high-functioning ASD (IQ > 70)

Study Title (brief): 
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Balovaptan in Adults with Autism Spectrum Disorder with a 2-Year Open Label Extension
Study Description (brief): 

This study will evaluate the efficacy, safety, and pharmacokinetics of 10mg of oral administration balovaptan QD compared with matching placebo in adults (18 years and older) with ASD.

Study Contact: 

Clinical Evaluation Center at 845-398-2184 or vrp@nki.rfmh.org.